Schizophrenia – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)

The schizophrenia therapy market remains highly competitive, dominated by atypical and typical antipsychotics. Ongoing generic erosion within the atypical class continues to shape psychiatrists’ prescribing behaviors, even as newer oral agents—such as Caplyta (Johnson & Johnson Innovative Medicine) and Cobenfy (Bristol Myers Squibb)—work to expand their adoption. The long-acting injectable (LAI) segment is also in transition, marked by intensifying competition, the launch of newer LAIs such as Abilify Asimtufii (Lundbeck/Otsuka) and Uzedy (Teva), and the genericization of key established brands. However, recent clinical setbacks—including failures of pimavanserin, roluperidone, and iclepertin—underscore the continued unmet need for efficacious therapies targeting negative symptoms and cognitive impairment associated with schizophrenia (CIAS). This report evaluates the market potential of emerging late-phase therapies such as brilaroxazine (Reviva) and milsaperidone (Vanda; Teva) and provides an in-depth profile of evenamide (Newron Pharmaceuticals), a Phase 3 sodium channel blocker being developed for treatment-resistant schizophrenia.

Questions answered

• What is the size of the schizophrenia therapy market in the major markets?
• Which factors drive and constrain the use of newer-to-market oral and LAIs of atypical antipsychotics? How is competition heating up in these segments?
• How will late-phase and newly launched brands alter competitive positioning and patient-share trajectories across the major markets?
• What are the areas of highest unmet need in schizophrenia treatment?
• How will patient share, branded–generic dynamics, and competitive pressures shift during the 10-year forecast period?

Content highlights

Geographies: United States, EU5, Japan

Primary research: 35 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other Clarivate research

Epidemiology: Prevalence of schizophrenia by country, segmented by symptom status; diagnosed / drug-treated prevalence of schizophrenia by country

Forecast: 10-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2035, segmented by brands /generics and epidemiological subpopulations

Drug treatments: Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.